4th Jun 2026 07:10
RNS REACH: RELEASE 4 June 2026
ImmuPharma PLC
("ImmuPharma" or the "Company")
Incanthera plc - Corporate Update & Board Changes
ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes today's announcement by Incanthera plc, "Incanthera", regarding a corporate update and subsequent Board changes. As part of the Board changes, Tim McCarthy has stepped down as Executive Chairman of Incanthera: Link: https://incanthera.com/ news-media/.
Ends
ImmuPharma PLC (www.immupharma.co.uk.) | |
Tim McCarthy, Chief Executive Officer and Chairman
| |
Lisa Baderoon, Head of Investor Relations | + 44 (0) 7721 413496
|
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin
Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney
SI Capital (Joint Broker) Nick Emerson | +44 (0) 203 368 8974
+44 (0) 203 650 3650
+44 (0) 1483 413500
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk.
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
Related Shares:
Immupharma